Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Andecaliximab, Placebo, Methotrexate, TNF Inhibitor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more

Conditions: Ankylosing Spondylitis
Interventions: Bimekizumab, Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more

Conditions: Rheumatoid Arthritis
Interventions: 89Zr-DFO-CZP; Drug
Lead sponsor: Robert Flavell, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn's Disease
Interventions: Certolizumab pegol (CDP870); Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 19
States / cities: Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more

Conditions: Rheumatoid Arthritis
Interventions: TNF inhibitors, DMARDs; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Nipocalimab, Certolizumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more

Conditions: Crohn Disease
Interventions: certolizumab pegol (CDP870, CZP), Placebo; Biological · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Pell City, Alabama • Colorado Springs, Colorado • Lakewood, Colorado + 21 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol (CDP870); Biological
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 47
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, TNF Inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Juvenile Spondyloarthritis
Interventions: Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX); Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Etanercept, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions: Pharmacokinetics of certolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CZP), Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 101
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more

Conditions: Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions: Anal Pap smear and HPV DNA testing; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 310 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, TNF Inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis (RA)
Interventions: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab; Drug
Lead sponsor: Dr. Larry W. Moreland; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions: Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord, Certolizumab Pegol; Procedure · Biological
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah

Conditions: Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions: e-Device; Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions: Not listed
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Crohn's Disease
Interventions: Cimzia, Mesalamine; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

RHYTHM (Formerly Escape II Myocardium)

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

COVID-19 VaccinE Response in Rheumatology Patients

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

UCB Cimzia Pregnancy Follow-up Study

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Cimzia Versus Mesalamine for Crohn's Recurrence